

Fig. 52

52 / 129

	Diversity	Equivalence	Prognosis Total (+) Vs (-)	Prognosis Total (homo)	Prognosis Total	Prognosis Total (+) vs (-)	Prognosis Total (homo)	Prognosis Stomach	Prognosis Stomach	Prognosis Total (+) vs (-)	Prognosis Total (homo)
DR	Diversity		Total	Total		Stomach	Stomach			Other cancers	Other cancers
5	arp_25	K=R		K(-)>hetero, Rhomo>hetero	RR78.8				RR71.4		
6	arp_24	FL	F=L		FI66.7	F(-)>(+)			LI60.9		
13	arp_17	AT	A=T	Ahomo>hetero, T(-) >hetero	AA76.6				AA67.8		
14	arp_16	AV	A=V	A(-)>hetero, Vhomo>hetero	VV78.8				VV71.4		
29	arp_1	AS	A=S		SS83.36				SS100	A(+)>(-) St. A, >(+)	Shomohetero> (-)
33	arp4	OR	O=R		OR68.3				RR68.1		
38	arp9	EKW	9K=11D=26Y=28H=30G		KW74.2				KW75.8		
39	arp10	EQY	10E=31V=38A=40Y= (1660)=(166R)		EY83.3				EY75		
40	arp11	DGLPSV	11G=13Y=14E=14=K25 Q=25R=30L, 11S=12K=12T, 11P=13R	V(-)>hetero	GV100, LL100Q				Vhetero>(-) LL100		Phetero>homo
41	arp12	KT			KK66.5				TT70.7		
42	arp13	FGHRSY	13F=31F=31I		HY100, FR71.6				SY100, GR75.4	F(+)>(-)	Fhetero>(-), Rhetero>homo Shetero, (-) >homo
43	arp14	EK	E=K		EE66.2				EK80		
45	arp16	HOY			HQ71.50				HQ830		
	arp25	OR	Q=R								
55	arp26	FLY			LY70.2				LY80.3		Fhetero>homo
57	arp28	DEH	28H=30G		DE69.2				DE69.4		
59	arp30	CDHLRY	30H=37L=38I=85A=85V		CC1000				CC1000		
60	arp31	FIV	31V=38A=40F=40Y, 31 (F=I)		FV77.8				FV76.2	I(+)>(-)	Fhetero>homo (hetero>(-)

(Cut-off data added as was present in Figure as originally filed)

53 / 129

Fig. 53

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Stomach	Other (-) cancers
DR	Diversity		Total	Total		Stomach	Stomach			Other cancers
61	arp32	HY	H=Y		HY66.9		YY68			
62	arp33	HN	H=N		NN66.7		HH71.4			
66	arp37	FLNSY	F=S		LL800		FS73.4			F(-) hetero:homo
67	arp38	ALV			LL800		AV78.8			
69	arp40	FY	F=Y		FY73.1		FY71.6			
76	arp47	FY	F=Y		FY67.4		YY68.9			
86	arp57	ADSV		Shetero (-)>homo	AV73.70		AD72.5, SV72.5			Shetero(-)> homo
87	arp58	AE	A=E		AE67		AE71.1			
89	arp60	HAY			HS73.7		HY68.4			
96	arp67	FIL			FI68.5		FI72.2			
99	arp70	DOR			DD69.4		DD72.7			
100	arp71	AEKR		K(-)>hetero	AR63.5, ER67.2, AE72.6		EK750			A,Enetero> homo
	arp73	AG	73A=73G=74R=74N= 77N=77T		AA66.3		AA68.1			
103	arp74	AEIQR	R=N		LR80		AO100.0			
106	arp77	NT	N=T		TT66.4		TT68.2			
107	arp78	VY	V=Y		VY67.1		VY68.6			

(Cut-off data added as was present in Figure as originally filed)

54 / 129

Fig. 54

		Diversity	Equivalence	Prognosis Total (+) vs (-)	Prognosis Total (homo)	Prognosis Total	Prognosis Total (+) vs (-)	Prognosis Total (homo)	Prognosis Stomach	Prognosis Stomach	Prognosis Stomach	Prognosis Total (+) vs (-)	Prognosis Other cancers	Prognosis Total (homo)
DR	Diversity			Total	Total				Stomach	Stomach			Other cancers	Other cancers
114	arp85	AV	A=V			AA80					VV68.1			
115	arp86	GV	G=V			GG68.5					VV69.4			
125	arp96	EHQY				EE100					EE100			Q(-) hetero+homo
127	arp98	EK	98E=98K=104A=142V			EK68.5					EK72.1			
133	arp104	AS	A=S			AS70.5					AS72.1			
149	arp120	NS	S=N		N(-) >hetero, Shomo>h etero	NN77.9					NN72.9			
162	arp133	LR	133L=133R=142M=142V			RR67.5					LL69.7	R(+)>(-)		
169	arp140	AT				TT71.5					TT74.1			
171	arp142	MV	M=V			VV67.5					MM69.7	V(+)>(-)		
178	arp149	HQY	H=Q			HH68.1					HH70.8			
	arp164	FV												
195	arp166	OR	O=R			RR67					QR68.6			
209	arp180	LV	L=V			LL75.1					RR68.6			
210	arp181	MT				TT67.3					LL70.1			
218	arp189	RS	R=S			SS100					TT69			
260	arp231	PQ	P=Q			QQ66.7					SS100			
262	arp233	RT	R=T			TT67.4	T(+)>(+)	R, Thomo>h etero, (-)			QQ67.9			R, Thetero(-) >homo
	All survived					DR11GLGV LL(5)					DR30CLC C(4)			

(Cut-off data added as was present in Figure as originally filed)

Fig. 55

			Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
	Diversit	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	Stomach cancer
DR	Diversit			Total	Total		Stomach	Stomach	
arp_25	KR	K=R	RR100						
arp_24	FL	F=L	FL100						
arp_17	AT	A=T	AA100			Immunotherapy AA 71.4			
arp16	AV	A=V	VV100						
arp1	AS	A=S	AA90.90						
arp4	OR	O=R	QQ69.3						
arp9	EKW	9K=11D=26V=28 H=30G	KW71.2			Immunotherapy KW (86.7)		Immunotherapy E (-), (homo)>hetero	Immunotherapy KW 84.6
arp10	EQY	10E=31V=38A=4 0Y=(166Q)=(166 R)	EY100	Immunotherapy E(-)>(+)	Immunotherapy E(-) >hetero		Immunotherap y E(-)>(+)	Immunotherapy E(-) >hetero	
arp11	DGLPS V	11G=13V=14E=1 4=K25Q=25R=3 0L. 11S=12K=12T. 11P=13R	LL1000		Immunotherapy V(homo,((-))>hetero	no adjuvant therapy DS(83.4)DV(79.6), Immunotherapy DP (84.6)		Immunotherapy V(homo,((-))>hetero	
arp12	KT		KK64.2						
arp13	FGHRS Y	13F=13F=31I	FR74.20	Immunotherapy Shetero>(-)>homo		no adjuvant therapy GH(89.9), Immunotherapy FS(81.9)		Immunotherapy H(homo,((-))>hetero	
arp14	EK	E=K	EE63.5						
arp16	HQY		QY100						
arp25	QR	Q=R							
arp26	FLY		LL100	Chemotherapy 26L(+)>(-)	Chemotherapy Lhetero>(-)>homo, Immunotherapy Lhetero,((-)>homo	no adjuvant therapy FL(87), Immunotherapy FL(61.4)		Chemotherapy Lhetero,((-)>homo, Immunotherapy Lhetero,((-)>homo	Immunotherapy LY66.7
arp28	DEH	28H=30G	EE63.3		Immunotherapy Ehetero,((-)>homo			Immunotherapy Ehetero,((-)>homo	Immunotherapy EH (68.6)
arp30	CGHLR Y	30H=37L=38L=8 5A=85V	CC100	no adjuvant therapy H(+)>(-) Immunotherapy R(-)>(+)	Immunotherapy R(-) >hetero		Immunotherap y R(-)>(+)		
arp31	FIV	31V=38A=40F=4 0Y, 31(F=1)	FV80	Immunotherapy V(-)>(+)	Immunotherapy V(-) >hetero	Immunotherapy FF (55.5) FI(60.7)	Immunotherap y V(-)>(+)	Immunotherapy V(-) >hetero	

(Cut-off data added as was present in Figure as originally filed)

Fig. 56

DR	Diversity	Equivalence	Prognosis		Treatment Effect		Treatment Effect		Treatment Effect		Treatment Effect		Treatment Effect	
			Other cancers	Total (+) vs (-)	Total	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	Stomach	Total (+) vs (-)	Total (homo)	Stomach cancer	Stomach
arp32	HY	H=Y	HY64.8											
arp33	HN	H=N	HN64.5											
arp37	FLNSY	F=S	FL63.30	Chemotherapy F(-)>(+) no adjuvant therapy L (+)>(-), immunotherapy N(+)>(-)	Chemotherapy F(-) >hetero, homo immunotherapy Nhetero (homo)>(-) immunotherapy A(-) no adjuvant therapy L(+)>(-)	Chemotherapy F(-) >hetero, homo immunotherapy Nhetero (homo)>(-) immunotherapy A(-) >hetero	Chemotherapy LY(70.9) immunotherapy NS(72.5)							
arp38	ALV		LL100	immunotherapy A(-)>(+) no adjuvant therapy L(+)>(-)	immunotherapy A(-) >hetero	immunotherapy A(-) >hetero								
arp40	FY	F=Y	FY75	immunotherapy Y(-)>(+)	immunotherapy Fromo>hetero immunotherapy Y(-) >hetero	immunotherapy FF(67.5)								
arp47	FY	F=Y	FY67.3	Chemotherapy A(-)>(+)	no adjuvant therapy Shetero (-)>homo	no adjuvant therapy SV(62.2), Chemotherapy DD(60.3), immunotherapy AD(76.2)								
arp57	ADSV		AV88.90	Chemotherapy A(-)>(+)	no adjuvant therapy Shetero (-)>homo	no adjuvant therapy SV(62.2), Chemotherapy DD(60.3), immunotherapy AD(76.2)								
arp58	AE	A=E	AA63.5	Chemotherapy H(-)>(+)		Chemotherapy YY (56.8)								
arp60	HAY		HS88.9	immunotherapy (-)>(+)										
arp67	FIL		FF72.4	Chemotherapy L(-)>(+)	immunotherapy L(-) >homo, hetero, no adjuvant therapy Lhetero(-)>homo, Chemotherapy L(-) >hetero, homo	no adjuvant therapy IL(82.8), Chemotherapy FI(63.4), immunotherapy FI(66)								
arp70	DOR		RR69.4	Chemotherapy R(-)>(+)										
arp71	AEKR		KR78.80	no adjuvant therapy K(-) >(+)	no adjuvant therapy Ahetero, (-)>homo Ehetero, (-)>homo	no adjuvant therapy RR(81.8), immunotherapy ER(73.7)								
arp73	AG	73A=73G=74 R=74N=77N=77T	AG65.6											
arp74	AELOQ	R=N	ER1000	Chemotherapy E(-)>(+) immunotherapy E(+)>(-)	immunotherapy Ahetero (-)>homo immunotherapy/ Ehetero, homo>(-)	immunotherapy AE(67.9)								
arp77	NI	N=T	NI83.3											
arp78	VY	V=Y	VV69.3											

(Cut-off data added as was present in Figure as originally filed)

58 / 129

Fig. 58

			Treatment Effect	Treatment Effect	DR	DR	DR	DR
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)
DR	Diversity		Other cancers	Other cancers				
ap 25	KR	K=R						
ap 24	FL	F=L					FL80 LL22 90	
ap 17	AT	A=T						
ap 16	AV	A=V						
ap 1	AS	A=S			no adjuvant therapy AA(100)			AS70 3, AA44 40
ap 4	QR	Q=R			no adjuvant therapy KW(68.9)			
ap 9	EKW	9K=11D=26Y =28H=30G		no adjuvant therapy Whetero (-) homo				
ap 10	EOY	10E=31V=38A =40Y=(1660) =(166R)						
ap 11	DGLPSV	11G=13Y=14 E=14=K25Q=25R=30L 11S=12K=12T 11P=13R		no adjuvant therapy Phetero (-) homo				
ap 12	KT							
ap 13	FGHRSY	13F=31F=31I		no adjuvant therapy Rhetero (-) homo Chemotherapy Shetero (-) homo Immunotherapy Shetero (-) homo	no adjuvant therapy FR(90) Chemotherapy FR(72) Immunotherapy FS(100)		FT22 6, FF0, GR0, O	
ap 14	EK	E=K						
ap 16	HQY							
ap 25	QR	Q=R						QQ100, YY6, 30
ap 26	FLY			Chemotherapy F(-) hetero homo Chemotherapy hetero (-) homo				
ap 28	DEH	28H=30G			Chemotherapy EE(100)			
ap 30	CDHLRY	30H=37L=38L =85A=86V 31V=38A=40F =40Y, 31(F=1)						
ap 31	FIV							

(Cut-off data added as was present in Figure as originally filed)

59 / 129

Fig. 59

	Diversity	Equivalence	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	DR Cancer in Family	DR Metastases	DR Total (ratio of advanced cancer)	DR Smoking
DR	Diversity		Other cancers	Other cancers					
ap32	HY	H=Y	Chemotherapy Y(+)>(-) Immunotherapy Y(+)>(-) Chemotherapy H(-)>(+)	Chemotherapy H(-))hetero>homo, Immunotherapy hetero (-)hetero homo>(-) Yhetero homo>(-) Immunotherapy Yhetero homo>(-)	Chemotherapy HY(55.6) Immunotherapy HY(55.6)				
ap33	HN	H=N						HN18.3 NN9.80	
ap37	FLNSY	F=S		Chemotherapy F(-)hetero>homo, no adjuvant therapy Shetero (-)homo	no adjuvant therapy YY(81.3) Chemotherapy FS(100) Immunotherapy NS(80)	#			
ap38	ALV								
ap40	FY	F=Y							
ap47	FY	F=Y							
ap57	ADSV		Chemotherapy A(-)>(+)	Chemotherapy A(-)> (hetero) homo, Immunotherapy Shetero (-)homo	no adjuvant therapy SV(81.9) Chemotherapy VY(85.7) Immunotherapy DS(70.8)				
ap58	AE	A=E							
ap60	HAY			Chemotherapy H(-)hetero) homo	Chemotherapy SS(85.7) Immunotherapy HT(75) no adjuvant therapy FF(85.7) IL(6.3)				
ap67	FIL								
ap70	DOR								
ap71	AEKR			no adjuvant therapy Ahetero ((-))>homo	no adjuvant therapy AR(74.9)				
ap73	AG	73A=73G=74 R=74N=77N=77							
ap74	AELOK	R=N	no adjuvant therapy L(-)>(+)	no adjuvant therapy Ahetero (-)>homo	no adjuvant therapy(AE81) Chemotherapy (AE54.4)				
ap77	NT	N=T							
ap78	VY	V=Y							

(Cut-off data added as was present in Figure as originally filed)

60 / 129

Fig. 60

		Treatment Effect	Treatment Effect	Treatment Effect	DR	DR	DR	DR
Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)	Smoking
DR	Diversity	Other cancers	Other cancers					
ap85	AV	A=V	Chemotherapy G(+)>(-)	Chemotherapy G(+)>(-)	AV38.1 A=0.0	#		
ap86	GV	G=V	Chemotherapy G(+)>(-)	Chemotherapy G(+)>(-)				
ap96	EHQY		Chemotherapy Q(+)>(-)	Chemotherapy Q(+)>(-)				
ap98	EK	98E=98K=104 A=104S	Immunotherapy K(+)>(-)	Immunotherapy E(+)>(-)	Immunotherapy EK(88.4)			
ap104	AS	A=S	Immunotherapy S(+)>(-)	Immunotherapy A(+)>(-)	Immunotherapy AS(61.9)			
ap120	NS	S=N	no adjuvant therapy	no adjuvant therapy	#			
ap133	LR	133L=133R=1 42M=142V	no adjuvant therapy	no adjuvant therapy				
ap140	AT		no adjuvant therapy	no adjuvant therapy				
ap142	MV	M=V	no adjuvant therapy	no adjuvant therapy				
ap146	HOY	H=Q	no adjuvant therapy	no adjuvant therapy				
ap164	FV							
ap166	QR	Q=R						
ap180	LV	L=V						
ap181	MT							
ap189	RS	R=S						
ap231	PO	P=Q						
ap233	RT	R=T	Immunotherapy T(+)>(-)	Immunotherapy R(+)>(-)	Immunotherapy RT(77.9)			
All	survived							

(Cut-off data added as was present in Figure as originally filed)

61 / 129

$$\{ \text{ano} \} \{ \sim \}$$

(Cut-off data added as was present in Figure as originally filed)

62 / 129

(Cut-off data added as was present in Figure as originally filed)

63 / 129

Fig. 63

	Treatment Effect		Treatment Effect		Treatment Effect		Treatment Effect		DP	Metastases
	Total (+) vs (-)	Total (homo)	Stomach cancer	Total (+) vs (-)	Total (homo)	Other cancers	Other cancers	Category/rate of malignancy		
DP Diversity	Stomach	Stomach		Other cancers	Other cancers					
app8 LV				no adjuvant therapy	no adjuvant therapy			V95.2 LL89.80		
app9 FHY	Immunotherapy H- V H-(-)(+)	Immunotherapy H- (homo)>hetero	Immunotherapy F- (67.1) FF(65)	no adjuvant therapy F(+)>(-)	no adjuvant therapy H- Fhetero homo(-), no adjuvant therapy H- (hetero)>homo			#		
app11 GL				no adjuvant therapy G(+)>(-)	no adjuvant therapy Ghetero homo(-), no adjuvant therapy L- (hetero)>homo			V95.2 LL89.80		
app35 FLY			Chemotherapy (FF)							
app36 AV		Chemotherapy A- (homo)>hetero Chemotherapy Vhomo(-) >hetero	Chemotherapy (VV)						#	
app5 ADE		Chemotherapy A- (homo)>hetero								AE44.8 AA10
app56 AE				no adjuvant therapy A(+)>(-)	no adjuvant therapy Ahetero(-), homo, no adjuvant therapy Ehetero(-), homo					
app57 DE				no adjuvant therapy E(+)>(-)	no adjuvant therapy Dhetero(-), homo, no adjuvant therapy Ehetero homo(-)					
app65 FIL				no adjuvant therapy L(+)>(-)	no adjuvant therapy Lhetero>homo, no adjuvant therapy Lhetero homo(-), no adjuvant therapy E- (hetero)>homo, no adjuvant therapy Lhetero homo(-)					
app69 EK	Immunotherapy E- (+)>(-)	no adjuvant therapy Ehetero(-), homo, immunotherapy E- (hetero)>homo, no adjuvant therapy Khetero>(homo)(-), immunotherapy Khetero, (hetero)>(-)	no adjuvant therapy EK (85.4), immunotherapy KK (58.3)	no adjuvant therapy K(+)>(-)						
app76 IMV		Chemotherapy (L-) (homo)>hetero	Chemotherapy MV(64)		no adjuvant therapy Vhetero(-)>homo			V95.6 LL66.70		
app84 DG								DD92.1 GG87.80		
app85 EG								EE92.1 GG87.80		
app86 AP								V92.1 MM87.60		

(Cut-off data added as was present in Figure as originally filed)